Gene therapy occupies a "really excellent place" after "extraordinary" scientific advances, several approvals, a plump development pipeline and a flurry of partnering deals, observed Geoff McDonough, president and CEO of Generation Bio. But despite their "unprecedented opportunities to provide durable benefit," version 1.0/2.0 gene therapies also bear significant mechanistic limitations that confine their usefulness to small populations and relatively rare indications.